Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 406 participants.
Also called NCT06579105
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 406 participants
- Sponsor
- Registry
-
NCT06579105 -
2024-512562-34-00
-
- Other papers using this trial's data
- Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Germany, Hungary, Japan, Poland, Slovakia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06579105. Randomized; triple masking; primary purpose treatment. Start 2024-10-08 (actual); primary completion 2025-12-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
- Acronym
- SOLSTICE
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Placebo (placebo matching AZD5004 film-coated tablet)
- Intervention (Drug)
- AZD5004
- Intervention (Drug)
- Semaglutide
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06579105- Content hash
2a6b6800f8eba6435bce22124ff5ddecdfb9485af1ef4844682a30e4b2a6940b